LumiraDx LtdNASDAQ:LMDXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.1800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.6000/ 2
- Ask / Lots1.5400/ 1
- Open / Previous Close0.0000 / 1.1800
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LMDX |
|---|---|---|
| 09:32 ET | 4191 | 1.2 |
| 09:42 ET | 100 | 1.19 |
| 09:46 ET | 200 | 1.19 |
| 09:51 ET | 333 | 1.1898 |
| 09:53 ET | 877 | 1.19 |
| 10:08 ET | 1100 | 1.19 |
| 10:13 ET | 7592 | 1.2 |
| 10:15 ET | 100 | 1.2 |
| 10:20 ET | 100 | 1.19 |
| 10:31 ET | 400 | 1.1801 |
| 10:44 ET | 100 | 1.1801 |
| 10:49 ET | 4600 | 1.21 |
| 10:51 ET | 1000 | 1.2 |
| 11:00 ET | 300 | 1.21 |
| 11:18 ET | 500 | 1.21 |
| 11:21 ET | 5700 | 1.205 |
| 11:32 ET | 1000 | 1.23 |
| 11:36 ET | 400 | 1.23 |
| 11:48 ET | 100 | 1.22 |
| 11:52 ET | 100 | 1.2 |
| 11:57 ET | 1000 | 1.22 |
| 12:01 ET | 500 | 1.18 |
| 12:06 ET | 100 | 1.195 |
| 12:33 ET | 1197 | 1.19 |
| 12:51 ET | 100 | 1.19 |
| 01:00 ET | 2200 | 1.19 |
| 01:02 ET | 3296 | 1.195 |
| 01:04 ET | 6384 | 1.21 |
| 01:49 ET | 100 | 1.19 |
| 02:00 ET | 27150 | 1.19 |
| 02:02 ET | 43114 | 1.18 |
| 02:20 ET | 3000 | 1.2 |
| 02:21 ET | 1000 | 1.2 |
| 02:48 ET | 100 | 1.1918 |
| 02:50 ET | 600 | 1.1952 |
| 03:14 ET | 100 | 1.195 |
| 03:28 ET | 7998 | 1.22 |
| 03:32 ET | 4300 | 1.19 |
| 03:35 ET | 1980 | 1.2 |
| 03:42 ET | 5200 | 1.205 |
| 03:51 ET | 698 | 1.2 |
| 03:53 ET | 2450 | 1.2 |
| 03:55 ET | 1970 | 1.18 |
| 03:57 ET | 1100 | 1.19 |
| 04:00 ET | 32366 | 1.18 |
Feb 6, 2023
LumiraDx Says COVID, Influenza Assay Gets Emergency Use Authorization From FDA, Validation From UK Health Security Agency, from 10:03AM ET on Monday Feb 06, 2023 by MT Newswires
10:03AM ET on Monday Feb 06, 2023 by MT NewswiresLumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay, from 8:00AM ET on Monday Feb 06, 2023 by GlobeNewswire
8:00AM ET on Monday Feb 06, 2023 by GlobeNewswire
Feb 1, 2023
LumiraDx Gets Noncompliance Notice From Nasdaq, from 3:29AM ET on Wednesday Feb 01, 2023 by MT Newswires
3:29AM ET on Wednesday Feb 01, 2023 by MT Newswires
Jan 31, 2023
BRIEF-Lumiradx Announces Commercial Shipment Of Its Point Of Care Nt-Probnp Test In Europe, from 6:12PM ET on Tuesday Jan 31, 2023 by Thomson Reuters
6:12PM ET on Tuesday Jan 31, 2023 by Thomson ReutersBRIEF-Lumiradx Announces Receipt Of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency, from 5:56PM ET on Tuesday Jan 31, 2023 by Thomson Reuters
5:56PM ET on Tuesday Jan 31, 2023 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LumiraDx Ltd | 194.8M | -1.0x | --- |
Accuray Inc | 297.9M | -24.7x | --- |
Tabula Rasa HealthCare Inc | 166.0M | -1.8x | --- |
Babylon Holdings Ltd | 309.3M | -0.4x | --- |
Computer Programs and Systems Inc | 425.7M | 23.0x | +33.77% |
Cutera Inc | 674.6M | -8.2x | -9.73% |
Company Information
LumiraDx Limited is a United Kingdom-based diagnostics company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched the LumiraDx Platform, which is an integrated system comprised of small, microfluidic test strips and secure digital connectivity. Its diagnostic testing solutions are being deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The Company has developed and received regulatory approvals for approximately 11 diagnostic tests for use with its instrument. In addition, the Company has a portfolio of COVID-19 testing solutions from the lab to point of need.
Contact Information
- Headquarters
- Windward 3, Regatta Office Park PO Box 1350GRAND CAYMAN, Cayman Islands KY1-1108
- Phone
- 178-643-0411
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder, Director
- Ron Zwanziger
- President - North American Commercial Operations
- Peter Scheu
- Co-Founder, Chief Technology Officer, Director
- Dave Scott
- Co-Founder, Chief Scientific Officer, Director
- Jerry McAleer
- Chief Financial Officer, Vice President, Global Operations
- Dorian LeBlanc
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $194.8M |
|---|---|
Revenue (TTM) | $331.6M |
Shares Outstanding | 165.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.23 |
Book Value | $0.79 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -57.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
